Salidroside
| CAS No. | 10338-51-9 | Cat. No. | BCP04178 |
| Name | Salidroside | ||
| Synonyms | |||
| Formula | C14H20O7 | M. Wt | 300.3 |
| Description | Salidroside inhibits the growth of various human cancer cell lines in concentration- and time-dependent manners, and the sensitivity to salidroside is different in those cancer cell lines. Salidroside could cause G1-phase or G2-phase arrest in different cancer cell lines, meanwhile, salidroside resultes in a decrease of CDK4, cyclin D1, cyclin B1 and Cdc2, and upregulates the levels of p27(Kip1) and p21(Cip1). Salidroside also alleviates cell viability loss and apoptotic cell death induced by H(2)O(2) stimulation in cultured NGF-differentiated PC12 cells by activating ERK1/2 pathway and inhibiting caspase-3 activation.Salidroside activates the PI3K/Akt pathway resulting in protective effects against MPP(+)-induced apoptosis in PC12 cells, which may be used in the treatment of Parkinson's disease (PD). | ||
| Pathways | PI3K/Akt/mTOR | ||
| Targets | mTOR | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.